LymphedemaV1, Main, Exploration, bibRecord, 000349

Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

Identifieur interne : 000349 ( Main/Exploration ); précédent : 000348; suivant : 000350

Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

Auteurs : Tessa G. Steenbruggen [Pays-Bas] ; Mette S. Van Ramshorst [Pays-Bas] ; Marleen Kok [Pays-Bas] ; Sabine C. Linn [Pays-Bas] ; Carolien H. Smorenburg [Pays-Bas] ; Gabe S. Sonke [Pays-Bas]

Source :

Drugs [ 1179-1950 ] ; 2017.

RBID : pubmed:28616845

Abstract

In the last decade, the systemic treatment approach for patients with early breast cancer has partly shifted from adjuvant treatment to neoadjuvant treatment. Systemic treatment administration started as a 'one size fits all' approach but is currently customized according to each breast cancer subtype. Systemic treatment in a neoadjuvant setting is at least as effective as in an adjuvant setting and has several additional advantages. First, it enables response monitoring and provides prognostic information; second, it downstages the tumor, allowing for less extensive surgery, improved cosmetic outcomes, and reduced postoperative complications such as lymphedema; and third, it enables early development of new treatment strategies by using pathological complete remission as a surrogate outcome of event-free and overall survival. In this review we give an overview of the current standard of neoadjuvant systemic treatment strategies for the three main subtypes of breast cancer: hormone receptor-positive, triple-negative, and human epidermal growth factor receptor 2-positive. Additionally, we summarize drugs that are under investigation for use in the neoadjuvant setting.

DOI: 10.1007/s40265-017-0774-5
PubMed: 28616845

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.</title>
<author><name sortKey="Steenbruggen, Tessa G" sort="Steenbruggen, Tessa G" uniqKey="Steenbruggen T" first="Tessa G" last="Steenbruggen">Tessa G. Steenbruggen</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Ramshorst, Mette S" sort="Van Ramshorst, Mette S" uniqKey="Van Ramshorst M" first="Mette S" last="Van Ramshorst">Mette S. Van Ramshorst</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kok, Marleen" sort="Kok, Marleen" uniqKey="Kok M" first="Marleen" last="Kok">Marleen Kok</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Linn, Sabine C" sort="Linn, Sabine C" uniqKey="Linn S" first="Sabine C" last="Linn">Sabine C. Linn</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smorenburg, Carolien H" sort="Smorenburg, Carolien H" uniqKey="Smorenburg C" first="Carolien H" last="Smorenburg">Carolien H. Smorenburg</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sonke, Gabe S" sort="Sonke, Gabe S" uniqKey="Sonke G" first="Gabe S" last="Sonke">Gabe S. Sonke</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. g.sonke@nki.nl.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28616845</idno>
<idno type="pmid">28616845</idno>
<idno type="doi">10.1007/s40265-017-0774-5</idno>
<idno type="wicri:Area/PubMed/Corpus">000145</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000145</idno>
<idno type="wicri:Area/PubMed/Curation">000145</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000145</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000145</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000145</idno>
<idno type="wicri:Area/Ncbi/Merge">009196</idno>
<idno type="wicri:Area/Ncbi/Curation">009196</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">009196</idno>
<idno type="wicri:Area/Main/Merge">000349</idno>
<idno type="wicri:Area/Main/Curation">000349</idno>
<idno type="wicri:Area/Main/Exploration">000349</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.</title>
<author><name sortKey="Steenbruggen, Tessa G" sort="Steenbruggen, Tessa G" uniqKey="Steenbruggen T" first="Tessa G" last="Steenbruggen">Tessa G. Steenbruggen</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Van Ramshorst, Mette S" sort="Van Ramshorst, Mette S" uniqKey="Van Ramshorst M" first="Mette S" last="Van Ramshorst">Mette S. Van Ramshorst</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kok, Marleen" sort="Kok, Marleen" uniqKey="Kok M" first="Marleen" last="Kok">Marleen Kok</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Linn, Sabine C" sort="Linn, Sabine C" uniqKey="Linn S" first="Sabine C" last="Linn">Sabine C. Linn</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Smorenburg, Carolien H" sort="Smorenburg, Carolien H" uniqKey="Smorenburg C" first="Carolien H" last="Smorenburg">Carolien H. Smorenburg</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Sonke, Gabe S" sort="Sonke, Gabe S" uniqKey="Sonke G" first="Gabe S" last="Sonke">Gabe S. Sonke</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. g.sonke@nki.nl.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Medical Oncology, Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Drugs</title>
<idno type="eISSN">1179-1950</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In the last decade, the systemic treatment approach for patients with early breast cancer has partly shifted from adjuvant treatment to neoadjuvant treatment. Systemic treatment administration started as a 'one size fits all' approach but is currently customized according to each breast cancer subtype. Systemic treatment in a neoadjuvant setting is at least as effective as in an adjuvant setting and has several additional advantages. First, it enables response monitoring and provides prognostic information; second, it downstages the tumor, allowing for less extensive surgery, improved cosmetic outcomes, and reduced postoperative complications such as lymphedema; and third, it enables early development of new treatment strategies by using pathological complete remission as a surrogate outcome of event-free and overall survival. In this review we give an overview of the current standard of neoadjuvant systemic treatment strategies for the three main subtypes of breast cancer: hormone receptor-positive, triple-negative, and human epidermal growth factor receptor 2-positive. Additionally, we summarize drugs that are under investigation for use in the neoadjuvant setting.</div>
</front>
</TEI>
<affiliations><list><country><li>Pays-Bas</li>
</country>
<region><li>Hollande-Septentrionale</li>
</region>
<settlement><li>Amsterdam</li>
</settlement>
</list>
<tree><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Steenbruggen, Tessa G" sort="Steenbruggen, Tessa G" uniqKey="Steenbruggen T" first="Tessa G" last="Steenbruggen">Tessa G. Steenbruggen</name>
</region>
<name sortKey="Kok, Marleen" sort="Kok, Marleen" uniqKey="Kok M" first="Marleen" last="Kok">Marleen Kok</name>
<name sortKey="Linn, Sabine C" sort="Linn, Sabine C" uniqKey="Linn S" first="Sabine C" last="Linn">Sabine C. Linn</name>
<name sortKey="Smorenburg, Carolien H" sort="Smorenburg, Carolien H" uniqKey="Smorenburg C" first="Carolien H" last="Smorenburg">Carolien H. Smorenburg</name>
<name sortKey="Sonke, Gabe S" sort="Sonke, Gabe S" uniqKey="Sonke G" first="Gabe S" last="Sonke">Gabe S. Sonke</name>
<name sortKey="Van Ramshorst, Mette S" sort="Van Ramshorst, Mette S" uniqKey="Van Ramshorst M" first="Mette S" last="Van Ramshorst">Mette S. Van Ramshorst</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000349 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000349 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:28616845
   |texte=   Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:28616845" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

Serveur d'exploration sur le lymphœdème

Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.

Source :

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.